| 2023-11-09 |
详情>>
股本变动：
变动后总股本798.21万股
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-120.61美元,归母净利润-9.58亿美元,同比去年增长-19.18%
|
| 2023-11-07 |
财报披露：
美东时间 2023-11-07 盘前发布财报
|
| 2023-08-09 |
详情>>
业绩披露：
2023年中报每股收益-39.35美元,归母净利润-3.12亿美元,同比去年增长36.12%
|
| 2023-05-22 |
详情>>
拆分方案：
每80.0000合并分成1.0000股
|
| 2023-05-10 |
详情>>
业绩披露：
2023年一季报每股收益-0.3美元,归母净利润-1.87亿美元,同比去年增长8.46%
|
| 2023-04-07 |
股东大会：
将于2023-05-04召开股东大会
会议内容 ▼▲
- 1.To elect four Class II directors identified in the accompanying proxy statement to serve as directors of the Board of Directors of Bright Health;
2.To ratify the appointment of Deloitte & Touche LLP as Bright Health’s independent registered public accounting firm for the year ending December 31, 2023;
3.To approve, on a non-binding advisory basis, the compensation paid to our named executive officers for 2022;
4.To approve the Bright Health Group, Inc. Amended and Restated 2021 Omnibus Incentive Plan;
5.To approve an amendment to our Ninth Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio of not less than 1-for-15 and not greater than 1-for-80 (the “Reverse Stock Split”), with the exact ratio and effective time of the Reverse Stock Split to be determined by the Board of Directors at any time within one year of the date of the Annual Meeting (the “Reverse Stock Split Proposal”);
6.To transact other business as may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
|
| 2023-03-16 |
详情>>
业绩披露：
2022年年报每股收益-2.38美元,归母净利润-14.95亿美元,同比去年增长-26.19%
|
| 2023-03-16 |
详情>>
业绩披露：
2020年年报每股收益-1.82美元,归母净利润-2.48亿美元,同比去年增长-98.22%
|
| 2022-11-14 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-1.28美元,归母净利润-8.04亿美元,同比去年增长-117.11%
|
| 2022-08-15 |
详情>>
业绩披露：
2022年中报每股收益-0.78美元,归母净利润-4.88亿美元,同比去年增长-600.77%
|
| 2022-08-15 |
详情>>
业绩披露：
2021年中报每股收益-0.46美元,归母净利润-6968万美元,同比去年增长-174.83%
|
| 2022-05-12 |
详情>>
业绩披露：
2022年一季报每股收益-0.32美元,归母净利润-2.04亿美元,同比去年增长-711.43%
|
| 2022-04-15 |
股东大会：
将于2022-05-13召开股东大会
会议内容 ▼▲
- 1.to elect four Class I directors identified in the accompanying proxy statement to serve as directors of the Board of Directors of Bright Health;
2.to ratify the appointment of Deloitte & Touche LLP as Bright Health’s independent registered public accounting firm for the year ending December 31, 2022;
3.to approve, on a non-binding advisory basis, the compensation paid to our named executive officers for 2021;
4.to approve, on a non-binding advisory basis, the preferred frequency of future advisory votes on executive compensation;
5.to transact other business as may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
|
| 2022-03-18 |
详情>>
业绩披露：
2021年年报每股收益-3.02美元,归母净利润-11.85亿美元,同比去年增长-376.92%
|
| 2021-11-15 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-1.19美元,归母净利润-3.7亿美元,同比去年增长-337.71%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-01-29 |
详情>>
内部人交易：
Schindelman Simeon共交易10笔
|